Panadol maker Haleon takes hit from currency headwinds
Currency fluctuations meant Haleon PLC (LSE:HLN, NYSE:HLN), the FTSE 100-listed Panadol and Sensodyne owner, saw year-on-year reported revenue by 0.6% to £2.78 billion in the third quarter. Stripping away the impact of the weaker US dollar, the consumer health giant's organic revenues increased by 6.1%.
Haleon reports marginal decline in third-quarter revenue
Haleon reported a marginal fall in its third-quarter revenue on Thursday, hurt by declines in its pain relief and digestive health segments.
Haleon gets target hike as UBS raises 'forever' sales target
Haleon PLC (LSE:HLN, NYSE:HLN) has received a price target upgrade from UBS ahead of its third quarter update on 31 October as it becomes increasingly confident over its longer-term revenue opportunities. Foreign exchange movements will affect this year's adjusted earnings, which UBS has trimmed by 3%, but that aside the Swiss bank believes the GSK spin-iut has shown it can deliver 4-6% organic sales growth.
Futura Medical in line for $5m milestone payment as Haleon's US Eroxon launch gets underway
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has secured a $5 million milestone payment following the US launch of its flagship product, Eroxon. The payment was triggered as Haleon, the company's distribution partner, began fulfilling online pre-orders and making fast-acting erectile dysfunction gel available in American retail stores.
HLN or PODD: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Haleon PLC Sponsored ADR (HLN) and Insulet (PODD). But which of these two stocks is more attractive to value investors?
Haleon's buy rating restated after Pfizer cuts down stake
UBS has reiterated its buy rating on Haleon PLC (LSE:HLN, NYSE:HLN) shares after news that former parent company Pfizer Inc (NYSE:PFE, ETR:PFE) further pared down its stake in the FTSE 100-listed Sensodyne and Panadol maker. Haleon, which comprises the former consumer divisions of Pfizer and GSK PLC (LSE:GSK, NYSE:GSK), agreed on an off-market purchase of approximately £230 million worth of its own shares after Pfizer said t was cutting its stake by around £2.1 billion.
Haleon buys back some shares as Pfizer sells down stake
Haleon PLC (LSE:HLN, NYSE:HLN) said it has agreed to buy £230 million of its own shares from former co-parent Pfizer Inc (NYSE:PFE, ETR:PFE), which offloaded almost a $3.3 billion stake in the Sensodyne maker. The FTSE 100 consumer health group said made the purchase at a price of 308p per share.
Sensodyne maker Haleon to raise stake in China JV
British consumer healthcare company Haleon said on Friday it has agreed to raise its stake in its Chinese joint venture by 33% for 4.47 billion yuan ($637.35 million), taking its ownership to 88%.
Haleon lays out pricing for £1bn bond offering
Haleon PLC (LSE:HLN, NYSE:HLN) has unveiled pricing for a near-£1 billion bond offering set to be carried out by its subsidiary this month. Some €750 million (£633 million) worth of Euro medium-term notes to mature in 2028 will be sold with a price of 2.875%, the FTSE 100-listed health firm announced Thursday.
Haleon: Defensive Consumer Healthcare Stock As Safe Haven
Haleon is a consumer healthcare company formed from a GSK and Pfizer merger, with a 50% share price increase since trading began. Financial results show strong cash flows, with a net profit of 754M GBP and EPS of 7.90 pence per share in the first half of the year. Investment thesis suggests writing put options due to the high EBITDA multiple, with the potential for decreasing net debt and increasing EBITDA in the future.
Haleon, Reckitt, Wizz Air: Stocks lifting despite global sell-off
While the FTSE 100 continues to suffer its worst session in recent times, dropping 2.5%, there are a handful of companies which have been able to buck the bearish trend. Out of London's blue chips, only Haleon and Reckitt have been able to lift into the green, up by 0.1% and 0.4% respectively.
Haleon a rare riser on tough day as Deutsche Bank hilts resilience
Haleon PLC (LSE:HLN, NYSE:HLN) interim results showed its resilience and dependability in very tough markets, suggests Deutsche Bank adding it deserves a higher rating. “The stock has been strong into results and the positive margin performance, along with some low season improvement in respiratory sell-out, is supporting the stock.
